Hims & Hers Health Faces a Storm of Legal Allegations and Market Fallout
The Federal Trade Commission (FTC), along with state authorities in Utah and Los Angeles County, has filed a comprehensive lawsuit against Hims & Hers Health, Inc., charging the telehealth platform with deceptive billing practices, failure to disclose subscription terms, and the unauthorized sharing of consumers’ sensitive health data with Meta Platforms and Snap Inc. The filing came on July 29, 2026, and the company’s shares plunged 16 percent intraday, the steepest slide since early May.
Core Allegations
Deceptive Billing and Subscription Misrepresentation The FTC claims Hims & Hers failed to clearly disclose that customers were enrolling in a paid subscription. Customers were also allegedly confronted with onerous cancellation procedures that effectively locked them into recurring payments.
Privacy Violations and Data Misuse The lawsuit accuses Hims & Hers of transmitting user health information—such as details about erectile dysfunction, hair loss, and mental health conditions—to Meta Platforms and Snap Inc. for targeted advertising without explicit consumer consent, violating both federal consumer protection laws and state privacy statutes.
State‑Level Complaints Utah and Los Angeles County allege that the company’s practices also breach state consumer protection codes, potentially exposing the firm to additional civil liabilities and punitive damages.
Market Repercussions
Immediately after the suit’s filing, Hims & Hers’ stock sank 12 percent on the NYSE, the largest single‑day drop in the past year. The company’s market cap of approximately $7 billion and a current share price of $29.32 reflect a sharp erosion of investor confidence. Analysts point to the company’s negative price‑to‑earnings ratio of -517.64, underscoring the looming threat to profitability.
Company Response
Hims & Hers issued a terse statement denouncing the lawsuit as “baseless,” asserting that its privacy policy and billing procedures are fully compliant with all applicable regulations. Despite this, the company’s legal team acknowledges the seriousness of the claims and has begun assembling a defense strategy.
Implications for the Telehealth Sector
The case signals a broader regulatory crackdown on digital health platforms that monetize user data while positioning themselves as privacy‑focused. Competitors are watching closely; any precedent set by the FTC could compel the industry to overhaul data‑handling protocols and subscription disclosures. Investors, meanwhile, face a dilemma: the company’s core telehealth services remain lucrative, yet the legal cloud threatens its valuation and long‑term viability.
The unfolding lawsuit underscores that in the age of digital health, consumer trust is not merely a marketing asset—it’s a legal shield. Hims & Hers’ future will hinge on how swiftly and transparently it can address these allegations and restore confidence among its users and shareholders.
